Friday, September 4, 2026

HAL Allergy and InfectoPharm partner on ENT DiGAs

HAL Allergy and InfectoPharm Arzneimittel und Consilium have entered into a strategic partnership for digital health applications in ear, nose and throat care. The multi-year cooperation starts with the joint commercialization of Meine Tinnitus App in Germany.

The application is permanently listed in the DiGA directory of Germany’s Federal Institute for Drugs and Medical Devices. The companies plan to combine their respective access to ENT specialists to support the use of digital therapy options in routine care.

Digital support for tinnitus care

Meine Tinnitus App is intended for adults with chronic subjective tinnitus. It is based on structured tinnitus counselling in line with guideline recommendations and can be used independently of time and location.

The program consists of twelve weekly modules with psychoeducational content and practical exercises. Topics include stress management, attention control and sleep hygiene. Physicians and psychotherapists can prescribe the DiGA for one year. According to the companies, statutory health insurers in Germany cover the full cost.

Partners plan to expand the portfolio

HAL Allergy contributes its presence among German ENT specialists to the collaboration. The Netherlands-based biopharma company focuses on allergen immunotherapies and biologics for inhalant allergies and insect venom allergies and is part of the Droege Group.

Heppenheim-based InfectoPharm points to a growing otology portfolio and experience with innovative healthcare offerings. Its Hamburg-based subsidiary InfectoPharm Digital Health develops prescription digital medical products and has Meine Tinnitus App as its current core product.

The partners plan to add another DiGA in the ENT field toward the end of 2026. This would broaden the digital portfolio beyond the tinnitus application.

Relevance for ENT practices

The agreement illustrates how pharmaceutical companies are positioning reimbursable digital applications as an addition to established treatment pathways. For ENT practices, the key issue will be how such tools fit into counselling, prescribing and follow-up in daily workflows.